Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases
about
The global intellectual property ecosystem for insulin and its public health implications: an observational study.Modeling HIV/AIDS drug price determinants in Brazil: is generic competition a myth?Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohortStrategies for price reduction of HIV medicines under a monopoly situation in Brazil.Factors influencing global antiretroviral procurement prices.The impact of the new WHO antiretroviral treatment guidelines on HIV epidemic dynamics and cost in South Africa.Enhancing medicine price transparency through price information mechanisms.Quantifying the impoverishing effects of purchasing medicines: a cross-country comparison of the affordability of medicines in the developing worldThe global pediatric antiretroviral market: analyses of product availability and utilization reveal challenges for development of pediatric formulations and HIV/AIDS treatment in children.Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.The cost-effectiveness of different feeding patterns combined with prompt treatments for preventing mother-to-child HIV transmission in South Africa: estimates from simulation modeling.Pharmacoeconomics guidelines: The need of hour for IndiaA lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countriesReducing outbreaks: using international governmental risk pools to fund research and development of infectious disease medicines and vaccines.Driving a decade of change: HIV/AIDS, patents and access to medicines for all.Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countriesThe HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020.Effectiveness of generic and proprietary first-line anti-retroviral regimens in a primary health care setting in Lusaka, Zambia: a cohort study.Monitoring of HIV treatment in seven countries in the WHO Region of the Americas.Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.Assessing the population health impact of market interventions to improve access to antiretroviral treatment.Trends in medicines procurement by the Brazilian federal government from 2006 to 2013.Taking stock of the ethical foundations of international health research: pragmatic lessons from the IU-Moi Academic Research Ethics Partnership.Could patents interfere with the development of a cardiovascular polypill?The market dynamics of generic medicines in the private sector of 19 low and middle income countries between 2001 and 2011: a descriptive time series analysisAffordability of adult HIV/AIDS treatment in developing countries: modelling price determinants for a better insight of the market functioningTherapy for HIV: past, present, and future.Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.Policy approaches to improve availability and affordability of medicines in Mexico - an example of a middle income country.Do national drug policies influence antiretroviral drug prices? Evidence from the Southern African Development community.Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz.Access to medicines, market failure and market intervention: a tale of two regimes.The Trans Pacific Partnership Agreement, intellectual property and medicines: Differential outcomes for developed and developing countries.
P2860
Q27316509-25AA5B30-7D2A-499E-B798-2CC8A2D94D38Q28476569-34E0A92E-2571-46BD-BB6E-03032B18EA07Q28477027-6459AC37-26C4-4121-8C99-29FCDF686413Q30386525-BB334F0B-7FC9-4B67-8E8B-EEF1D132D5DBQ30892581-3DC45470-6614-465A-A1AD-5CD5AA714FE5Q31026449-E932996C-CAB0-4E2B-8A16-A9ED4E93F7EDQ33606323-F95290DD-A743-4AC5-A311-6BDAEAB26E32Q33687205-D10B6536-88A5-4816-A2FD-088B459536BAQ33720016-A9099AAF-FBCB-4207-A02F-A86C9277ABFBQ33907223-5371EC85-BB5D-4FFF-ACF0-5C76C04A966FQ33940190-00026E32-D855-49D3-B3C5-8AE0C9FD0C1FQ34039245-AAA7DDCD-5278-4E6C-9F12-A1937FB8C990Q34152158-6673E2CA-CD57-437F-963F-7A37386957BBQ34637519-85B1DA92-715F-4830-A848-B8114B62CFFEQ34808796-894FC21A-C4C1-4EAD-B793-0815BBAE153EQ35061154-CB8812B1-864E-465D-ABE7-08C990FCD9D9Q35545912-1E977FAA-8A4C-4AAE-8BAE-FBFD78BFC0E8Q35850530-56CF9D28-A7F0-484D-AC48-916A6840AE27Q35883654-300BB97D-73A8-44E9-8A60-15CB76F45893Q36089490-B7380C9B-119A-43BE-BBCE-C51B6346CEEEQ36156655-6C476A1B-6C9F-4A34-B24B-22ADE9B836D2Q36201249-52CABC70-947A-46F3-BF23-1CBD76EF266FQ36339862-76CACB7E-124B-40C2-A0BC-009959F7E1B3Q37097211-41C872E6-6788-4660-918E-385C6EE1B26DQ37189186-2A66AE1B-048B-41E2-8A68-AAAFDD5B1816Q37207470-FC4DFB67-ED6A-4E7D-B564-A406B9C7F97EQ37355309-F27F579C-1D28-493E-81F8-7E6A4F7D345DQ37858308-F99FACAA-B0AC-4A23-A9BF-8D3857AE6EECQ38178581-DE2E4D20-ED41-4A6F-B30F-3916EBE47942Q38648419-5EB255E1-DAD4-447A-AA80-77C4559211CCQ38957818-1F9C9A01-CFE6-4EBC-9440-57926BC24757Q39040089-A21F7096-AAC1-49AC-BDB2-BE2D31F9E163Q39541569-2DAD2F1D-0F2A-47DF-B41E-B40E987E4C08Q54941435-0E13599C-A6C0-4B6B-ACFB-F7AE0E49357E
P2860
Global strategies to reduce the price of antiretroviral medicines: evidence from transactional databases
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Global strategies to reduce th ...... e from transactional databases
@en
Global strategies to reduce th ...... from transactional databases.
@nl
type
label
Global strategies to reduce th ...... e from transactional databases
@en
Global strategies to reduce th ...... from transactional databases.
@nl
prefLabel
Global strategies to reduce th ...... e from transactional databases
@en
Global strategies to reduce th ...... from transactional databases.
@nl
P2093
P2860
P50
P356
P1476
Global strategies to reduce th ...... e from transactional databases
@en
P2093
Alexis C King
Danielle A Lawrence
Hubert G Leufkens
P2860
P304
P356
10.2471/BLT.08.058925
P407
P577
2009-07-01T00:00:00Z